Publicacións nas que colabora con Vivencio Barrios Alonso (27)

2024

  1. New technologies for the diagnosis, treatment, and monitoring of cardiovascular diseases

    Revista Espanola de Cardiologia, Vol. 77, Núm. 1, pp. 88-96

2023

  1. Current situation of the comprehensive approach of heart failure in Spain. The OPTIMISE-IC project

    REC: CardioClinics, Vol. 58, Núm. 4, pp. 289-302

  2. Impact of Advanced Age on the Incidence of Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stable Coronary Artery Disease in a Real-World Setting in Spain

    Journal of Clinical Medicine, Vol. 12, Núm. 16

  3. Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban

    Journal of comparative effectiveness research, Vol. 12, Núm. 3, pp. e220049

  4. Selection of the best of 2022 in clinical cardiology and cardiovascular pharmacotherapy

    REC: CardioClinics, Vol. 58, pp. S49-S54

2022

  1. Assessment of medical management in Coronary Type 2 Diabetic patients with previous percutaneous coronary intervention in Spain: A retrospective analysis of electronic health records using Natural Language Processing

    PLoS ONE, Vol. 17, Núm. 2 February

  2. Comments on the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice

    Revista Española de Cardiología (English Edition), Vol. 75, Núm. 5, pp. 364-369

  3. Major Adverse Cardiovascular Events in Coronary Type 2 Diabetic Patients: Identification of Associated Factors Using Electronic Health Records and Natural Language Processing

    Journal of Clinical Medicine, Vol. 11, Núm. 20

  4. Prognostic value of a model based on IC-BERG recommendations in ambulatory patients with heart failure

    REC: CardioClinics, Vol. 57, Núm. 2, pp. 76-84

  5. Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries

    Journal of comparative effectiveness research, Vol. 11, Núm. 16, pp. 1173-1184

  6. Selection of the best of 2021 in clinical cardiology and COVID-19

    REC: CardioClinics, Vol. 57, pp. S17-S22

  7. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study

    European Journal of Clinical Investigation

2020

  1. Telemedicine consultation for the clinical cardiologists in the era of COVID-19: present and future. Consensus document of the Spanish Society of Cardiology

    Revista Espanola de Cardiologia, Vol. 73, Núm. 11, pp. 910-918

2019

  1. Comentarios a la guía ESC/ESH 2018 sobre el diagnóstico y tratamiento de la hipertensión arterial

    Revista Espanola de Cardiologia, Vol. 72, Núm. 2, pp. 104-108

  2. Lifestyle and cardiovascular risk factors in Spanish, Portuguese and Latin-American cardiologists. PREDICA survey

    REC: CardioClinics, Vol. 54, Núm. 1, pp. 17-26

  3. Lifestyle and cardiovascular risk factors in Spanish, Portuguese and Latin-American cardiologists. PREDICA survey

    REC: CardioClinics, Vol. 54, Núm. 1, pp. 17-26

  4. Quality of life, adherence and satisfaction of patients with auricular fibrillation treated with dabigatran or vitamin K antagonists

    Revista Clinica Espanola, Vol. 219, Núm. 6, pp. 285-292

2018

  1. Comments on the 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases

    Revista espanola de cardiologia (English ed.), Vol. 71, Núm. 2, pp. 74-78

  2. Rivaroxaban: searching the integral vascular protection

    Expert Review of Clinical Pharmacology, Vol. 11, Núm. 7, pp. 719-728

2016

  1. Selección de temas de actualidad en cardiología clínica, cardiología geriátrica e insuficiencia cardiaca y trasplante 2015

    Revista Espanola de Cardiologia, Vol. 69, Núm. 2, pp. 159-166